Other hypoglycaemic episodes during the treatment periods
hypoglycaemia
HYPOGLYCAEMIA
During the treatment periods, outside the period of hypoglycaemia induction experiments, there were no severe hypoglycaemic episodes (level 3), and the rate of clinically significant hypoglycaemic episodes (level 2) was comparable for icodec and glargine U100 (3.4 vs 3.0 episodes per participant-year of exposure, respectively). Furthermore, over both doses, the mean±SD duration of level 2 hypoglycaemic episodes was 25.3±8.5 min for icodec and 37.7±15.0 min for glargine U100. There were no level 2 hypoglycaemic episodes during the 48 h prior to any of the hypoglycaemia induction experiments.